Ergotamine D-tartrate

The effectiveness of dihydroergotamine (DHE) and ergotamine tartrate was demonstrated in old clinical trials which probably would not meet currently accepted criteria for good methodology. For ergotamine tartrate, the dose usually recommended is 1-2 mg/d not to exceed 6 mg/d or 10 mg/week. DHE, which has a low bioavailability, is only effective after parenteral administration (subcutaneous, intramuscular, intravenous, or nasal-spray administration). The recommended dose is 1-2 mg/d. 

Collet AM, Moncharmont D, San Marco JL, Eissinger F, Pinot JJ, Laselve L. Ergotisme ia-trc e role de Tassociation tartrate d ergotamine-propionate d erythromycine. Sem Hop Pan.s(1982)58,1624-6. 

Grolleau JY, Martin M, de la Guerrande B, Barrier J, Peltier P. Ergotism aigu lors d une as-sociationjosamycine/tartrate d ergotamine. Therapie (1981) 36,319-21. 

B orie B, Aimez P, Soria RJ, Samama F di Maria G, Guy-Grand B, Bour H. L association triacetyl oleandomycin-tartrate d ergotamine est-eUe dan reuse Nouv Presse Med (1975) 4, 2723-5. 

Baudouy PY, Mellat M, Velleteau de MouUiac M. Infarctus du myocarde provoque par Fassociation tartrate d ergotamine-troleandomycine. RevMedInteme (1988) 9,420-2. 

KoWer D. Aerosols for systemic treatment. Lung 1990 168(suppl) 677-684. Graham JR, Malvea BP, Gramm HF. Aerosol ergotamine tartrate for migraine and Horton s syndrome. N Engl J Med 1960 263 802-804. 

---